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Abstract
Objective To evaluate early results of transsphenoidal surgery for pituitary adenomas.
Design Retrospective evaluation of 90 consecutive patients undergoing endoscopic pituitary adenoma surgery (2007–2016) at
“Maggiore della Carità” Hospital in Novara, Italy. Age at diagnosis, sex, symptoms at presentation, hormonal and radiological
data, complications of surgery, and short-term follow-up information were collected.
Results The majority of patients were male (M/F: 1.5/1, mean age at diagnosis 62.1 ± 1.5 years mean ± SEM). Most patients
(91.1%) presented with a macroadenoma (27.4 mm ± 1.1 mm mean ± SEM), while 77.8% were non-functioning pituitary
adenomas. Clinical presentations related to mass effect were visual impairment (74.0%) and/or hypopituitarism (55.1%). The
main surgery complication was insipidus diabetes (12.2%), followed by cerebral hemorrhage (4.4%), cerebrospinal fluid (CSF)
leaks (4.4%), syndrome of inappropriate antidiuresis (SIAD) (2.2%), and epistaxis (2.2%); only one patient died because of
stroke. Risk of complications was not associated with tumor size (OR = 0.588, 95% CI 0.967–1.081, p = 0.443). Visual function
improved in 70.6% of patients, while recovery of normal pituitary function occurred in 48.1%. Early neuroimaging studies
demonstrated no residual tumor in 27.6% of patients. Invasion of cavernous sinus (OR = 3.293, 95% CI 0.897–16.738, p = 0.05)
and maximum tumor diameter (OR = 6.857, 95% CI 1.039–1.309, p < 0.01) were associated with an unfavorable surgical
outcome.
Conclusions Transsphenoidal endoscopic surgery for pituitary adenomas is safe and is frequently followed by improvement in
visual symptoms, whereas recovery of pituitary function is less common. In our patients, complete surgical removal of adenomas
is comparable to that of other series, but further investigations will be necessary to clarify the long-term risk of tumor recurrence.
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Introduction
Pituitary adenomas are benign epithelial tumors that arise
from adenohypophysial cells and constitute the most common
lesions in the hypothalamic/pituitary region, representing ~
10–20% of all intracranial tumors. Pituitary adenomas are
broadly classified into hormone-active tumors, which cause
specific clinical syndromes due to hormone hypersecretion,
and non-functioning pituitary adenomas (NFPAs) [1].
The management of choice for patients with pituitary
adenomas is neurosurgery, with the goal of complete tumor
removal with preservation of the pituitary gland. In the late
1960s, pituitary surgery evolved from a craniotomy ap-
proach toward less invasive approaches, in particular micro-
scopic and endoscopic. The transsphenoidal route is a direct
and minimally invasive extracerebral approach to the sellar
region and, therefore, it is the most widely used technique
for interventions involving this area [2].
The endoscopic technique allows dynamic panoramic
views, while angled scopes facilitate identification of
the parasellar extensions not visualized by the micro-
scope [3]. The advantages of this technique are minimal
postoperative discomfort, lower complication rate, quick
postoperative recovery rate, short hospital stay, and ef-
ficacy [4–6].
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Among the serious postoperative complications reported
after endoscopic transsphenoidal surgery, cerebrospinal fluid
leak is the most common, ranging from 1 to 6% of cases [2, 4,
7]. Operative mortalities, postoperative hemorrhages, and
meningitis are rare, reported in less than 1% of cases [8, 9].
The aim of the present study was to evaluate retrospective-
ly the clinical features and the pathohistological classification
of pituitary adenomas treated via endoscopic transsphenoidal
neurosurgery in our Hospital, analyzing the postoperative
complications of the endoscopic transsphenoidal approach,
and evaluating the clinical outcome and their course to
short-term follow-up.
Patients and methods
Patients
Between 2007 and 2016, data from 90 patients who
underwent a transnasal transsphenoidal endoscopic resection
for pituitary adenoma presenting to the Division of
Neurosurgery of the University Hospital “Maggiore della
Carità” in Novara, Italy, were retrospectively collected.
Patients were enrolled in this study based on the following
criteria: (i) imaging features suggestive of pituitary adenoma,
(ii) absence or presence of any biochemical and clinical evi-
dence of hormonal excess, and (iii) at least one sequential
magnetic resonance imaging (MRI) during the follow-up. In
the entire population, endocrinological, ophthalmological,
and neuroradiological examinations that took place before
and after surgery were considered. Demographic assessment
at the time of the operation was collected. Moreover, hormon-
al data, MRI, and visual field at diagnosis were retrospectively
recorded. Postoperative complications and short-term follow-
up data were collected. Specifically, short-term follow-up in-
formation was obtained by hormonal evaluation on the third
day, and 1 and 3 months after surgery, while MRI and oph-
thalmological evaluation were performed 1 and 3 months after
surgery.
The study protocol was approved by local ethics committee
and written informed consent was obtained from all subjects.
Methods
Hormonal evaluation
Laboratory data were obtained from the hospital central labo-
ratory. Hormonal evaluation included cortisol, corticotropin
(ACTH), free thyroxine (FT4), thyrotropin (TSH), prolactin
(PRL), growth hormone (GH), insulin-like grown factor (IGF-
I), luteinizing hormone (LH), follicle-stimulating hormone
(FSH), testosterone (in males), and estradiol (in females).
A diagnosis of hypogonadotropic hypogonadism was
reached in premenopausal women with amenorrhea, low es-
tradiol, and low-normal gonadotropin levels, and in men with
subnormal testosterone levels and low-normal gonadotropin
levels. Secondary hypothyroidism was diagnosed in patients
with low FT4 levels and normal or low TSH concentration.
Secondary hypoadrenalism was diagnosed in patients with
low morning cortisol levels below 10 μgr/dL associated with
a cortisol peak below 18 μg/dL in the short Synacthen test or
ITT and/or clinical symptoms of hypoadrenalism that im-
proved with replacement therapy with glucocorticoids.
Hyperprolactinemia was defined as a PRL level > 20 ng/mL
in women and > 15 ng/mL in men. Permanent diabetes
insipidus was diagnosed when hypotonic polyuria (> 40 mL/
kg body weight daily) ensued soon after surgery and lasted for
2 months. GH deficiency was defined by insufficient rise in
GH levels after stimulation either during the GHRH-arginine
test or during an insulin tolerance test (ITT) [10–12].
Neuroradiological evaluation
The tumor size was usually evaluated by MRI of the pituitary
fossa and, when this was contraindicated, by computer tomog-
raphy (CT) scan. The MRI included focused T1-weighted
sagittal and coronal views and T2-weighted axial scans using
a 0.5–1.5 T scanner depending on the study period. All scans
were reviewed by an expert neuroradiologist blinded to the
data of the study. Tumors were considered invasive of the
cavernous sinus if they corresponded to grade 3 or grade 4
in the classification of Knosp and coworkers [13]. Tumors
intraoperatively observed to be invading the sellar floor were
considered invasive of the sphenoid sinus.
Recurrence was defined as the appearance of an apparently
completely resected pituitary tumor (no visible remnant on
first postoperative imaging) or regrowth of a surgical remnant
(more than 2-mm increase).
Ophthalmological evaluation
Evaluation of visual function was obtained by the assessment
of visual acuity and visual field using a Goldmann perimeter.
Surgical procedure and histological analysis
The surgical procedures were performed in all patients by a
neurosurgeon together with an otorhinolaryngologist using
transnasal transsphenoidal endoscopic surgery.
Hematoxylin and eosin-stained sections were used for his-
topathological diagnosis. Standard immunocytochemistry
employing commercially available antisera was applied to
characterize neoplastic areas for the presence of PRL, growth
hormone (GH), ACTH, TSH, LH, and FSH.
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Statistical analysis
The results were expressed as mean ± standard error of the
mean (SEM) or percentage. Multivariate logistic regression
was used in the cases of hypopituitarism and unfavorable tu-
mor size (outcomes) to investigate possible covariates and
factors associated with them. Continuous variables were ana-
lyzed using Student’s t test. Chi-square was used to identify
significant associations between variables of interest. p values
less than 0.05 were considered significant. The dependent
variables were hypopituitarism and unfavorable tumor size.
The independent variables were the tumor characteristics or
complications, evaluated separately. The analyses were per-
formed using SPSS 21.0 (SPSS Inc., Chicago, Ill., USA).
Results
Preoperative evaluation
Most of the patients were male (M/F: 1.5/1) and mean age at
diagnosis (mean ± SEM) was 62.1 ± 1.5 years (range 22–
82 years).
Most of the patients (91.1%) presented with a macroadenoma
(maximumdiametermean ± SEM: 27.4 ± 1.1mm).NFPAswere
77.8% (N = 70) of the total series, while the remaining 22.2%
were hormone-secreting adenomas (62.5% GH-, 25% ACTH-,
12.5% PRL-secreting adenomas resistant to medical treatment).
Pathological features of these tumors at diagnosis are presented
in Table 1 and are stratified as functioning and non-functioning
adenomas. Clinical presentation of NFPAs was related to mass
effect as visual impairment in 74.0% of cases. Invasion of the
cavernous sinus was present in 74.2% of patients, the invasion of
sphenoidal sinus in 40.9%, the suprasellar extension in 51.5% of
cases, and at least one type of invasion was present in 90.9% of
NFPAs. As expected, the mean diameter was associated with the
risk of visual defects at diagnosis (OR= 4.304, p = 0.025).
Pituitary hormone deficits attributed to the pituitary lesion
were detected in 55.1% of cases and replacement therapy ac-
cording to the clinical guidelines [14] was prescribed, as
shown in Fig. 1.
Tumor diameter, extrasellar extension, and sinus invasions
were statistically associated with the presence of hypopituita-
rism at diagnosis (OR = 3.688, p = 0.05; OR = 3.365, p =
0.005, respectively).
Surgical complications
The most frequent surgical complication was diabetes insipidus
(12.2%), 11.1 and 1.1% transient and permanent, respectively,
followed by cerebral hemorrhage (4.4%), cerebra-spinal fluid
(CSF) rhinorrhea (4.4%), syndrome of inappropriate
antidiuresis (SIAD) (2.2%), and epistaxis (2.2%) (Table 2).
Risk of intraoperative complications was not statistically asso-
ciated with tumor size (OR = 0.588, p = 0.443).
Early postoperative results
Visual function improved in 70.6% of patients who presented
visual defects at diagnosis, while recovery of normal gonadal,
thyroid, or adrenal function occurred in 48.1% of cases.
Postoperative hypopituitarism was present in 55.7% of
cases, as shown in Fig. 2. Considering only patients with
normal pituitary function before surgery, postoperative wors-
ening of gonadal, thyroid, or adrenal function occurred in
29.2% of patients.
The risk of hypopituitarism was statistically associated
with invasive tumor (OR = 3.869, p = 0.042), but not with
tumor size and not with the presence of surgery complications
(OR = 2.087, p = 0.201).
Table 1 Preoperative
pathological features of NFPA
and FPA patients
NFPAs FPAs
N % 95% CI N % 95% CI
Macroadenoma 66/70 94.30 86.21–97.76 16/20 80 58.40–91.93
Previous pituitary surgery 6/64 9.4 4.37–18.98 0/20 0 0.00–16.11
Visual symptoms 37/50 74 60.45–84.13 4/18 22.2 9.00–45.21
IperPRL 12/33 36.4 22.19–53.38 5/20 25 11.19–46.87
Hypopituitarism 27/49 55.1 41.32–68.15 4/18 22.2 9.00–45.21
Invasivity 60/66 90.9 81.55–95.77 13/20 65 43.29–81.88
Suprasellar extension 34/66 51.5 39.71–63.15 4/20 20 8.07–41.60
Cavernosus sinus invasion 49/66 74.2 62.57–83.25 13/20 65 43.29–81.88
Sphenoidal sinus invasion 27/66 40.9 29.87–52.95 5/20 25 11.19–46.87
Data are presented as absolute and relative (%) frequencies
NFPAs, non-functioning pituitary adenomas; FPAs, functioning pituitary adenomas; PRL, prolactinemia; CI,
confidence interval
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Surgical outcome
The first postoperative neuroimaging studies demonstrated resid-
ual tumor in 72.4% of cases (mean size 10.3 ± 2 mm), whereas
no tumor residue was documented in 27.6% of patients.
Multivariate logistic regression analysis showed that tumor
invasion of the cavernous sinus (OR = 3.293, p = 0.05) and
maximum tumor diameter (OR = 6.857, p = 0.002) were asso-
ciated with an unfavorable surgical outcome.
Discussion
The aim of surgical treatment of pituitary adenoma is to re-
verse endocrine dysfunction and/or resolve the compressive
symptoms, with preservation of normal pituitary function. The
introduction of the endoscopic approach improved surgical
visualization, leading to a greater extent of resection with im-
proved safety [4–6].
In our series of patients who underwent transsphenoidal
surgery, low rates of perioperative mortality and major com-
plications (4.4%) were reported, except for cerebral hemor-
rhage, probably due to the very large size of the treated lesions
(4.4%). However, our results are likely similar to those de-
scribed by other pituitary surgical teams [9, 15].
Postoperative hypopituitarism is a well-known complica-
tion of pituitary surgery and many patients require pituitary
hormone replacement medications; however, most of these
patients are able to discontinue therapy within 2 to 6 months
after surgery. The reported incidence of diabetes insipidus is
0.5–15% [16–18], similar to our result (12.2%), while other
series reported a lower incidence [2, 7], probably because of
different definitions of this pathological condition that make it
difficult to compare surgical series. Regarding anterior pitui-
tary function, new cases of hypopituitarism occurred in ap-
proximately 29% of patients in our series; this prevalence is
higher by comparison with other series [9], but the short-term
follow-up of our study might not permit further validation. On
Table 2 Complications of transsphenoidal pituitary surgery
NFPAs FPAs All
N % 95% CI N % 95% CI N % 95% CI
Any complication 18/70 25.7 16.93–37.03 5/20 25 11.19–46.7 23/90 25.5 17.67–35.44
Cerebral hemorrhage 4/70 5.7 2.24–13.79 0/20 0 0.00–16.11 4/90 4.4 1.74–10.88
CSF leaks 4/70 5.7 2.24–13.79 0/20 0 0.00–16.11 4/90 4.4 1.74–10.88
Epistaxis 2/70 2.86 0.79–9.83 0/20 0 0.00–16.11 2/90 2.2 00.61–7.74
SIAD 1/70 1.4 00.25–7.66 1/20 5 0.89–23.61 2/90 2.2 00.61–7.74
Transient diabetes insipidus 7/70 10 4.93–19.23 3/20 15 5.24–36.06 10/90 11.1 6.15–19.26
Permanent diabetes insipidus 1/70 1.4 00.25–7.66 0/20 0 0.00–16.11 1/90 1.1 00.20–6.03
Data are presented as absolute and relative (%) frequencies
NFPs, non-functioning pituitary adenomas; FPAs, functioning pituitary adenomas; CSF, cerebrospinal fluid; SIAD, syndrome of inappropriate
antidiuresis; CI, confidence interval
Fig. 1 Frequency of preoperative hypopituitarism in NFPAs. Multiple:
presence of two or more pituitary deficits, excluding panhypopituitarism
Fig. 2 Postsurgical hypopituitarism. Multiple: presence of two or more
pituitary deficits, excluding panhypopituitarism
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the other hand, in the case of hypopituitarism secondary to the
pituitary adenoma, surgical removal could restore pituitary
hormonal function [19, 20], as confirmed in 48.1% of our
patients with impaired preoperative function. Similar results
were reported by different authors [9], whereas others have
reported either no improvement [16, 21] or even a worsening
of pituitary function [22]. Some authors speculated that im-
proved visualization of the normal pituitary gland during en-
doscopic surgery may allow better preservation of the remain-
ing gland and lead to improved functional outcomes [3].
It is well known that progressive visual impairment is a
hallmark symptom of pituitary adenomas when growth ex-
tends into the suprasellar space and causes compression of
the optic chiasm. Our findings showed that visual function
improved after surgery in 70.6% of our patients, thus
confirming the results reported by other authors [19, 23].
This is probably related to the use of the transsphenoidal ap-
proach, which causes less trauma to the optic pathway than the
transcranial route. However, few cases of postsurgery visual
impairment seem to be related to surgical hemorrhagic com-
plications [8].
We achieved apparent complete surgical removal of
the tumor in approximately 30% of our patients. In a
large series by Losa et al., the authors reported complete
tumor removal in 63% of 491 patients [9]. Frank et al.
reported a total resection of 77% of their 173 cases [2].
The surgical outcomes achieved in smaller series seem
less favorable, ranging from 14.3 to 43.1% [22–26], sim-
ilar to our findings. The clinical features which seem to
negatively affect the surgical outcome in multivariate
analysis were cavernous sinus invasion and increasing
maximum tumor diameter. Invasion of the cavernous si-
nus was also reported as the strongest independent neg-
ative predictor of complete surgical removal in another
study that used multivariate analysis [26] and was con-
firmed by Losa et al. [9].
In conclusion, the rates of gross tumor removal, although
as yet not sufficiently high, resolution of hormonal hyperse-
cretion, and improvement in visual symptoms confirm the
effectiveness of endoscopic pituitary surgery. The safety of
the procedure is similarly supported by the low reported inci-
dence of complications.
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